CTOs on the Move

Amplity

www.amplity.com

 
You knew us as PHS Health Solutions, Touchpoint, Tardis Medical, and PDI, a family of leading pharmaceutical contract commercial organizations with a reputation as a trusted partner to our clients. And we`re still all that - but now we`re Amplity Health. Our vision is singular, so we wanted our corporate identity to match. We`ve consolidated our family of brands to offer customized and multichannel medical, remote engagement, and sales solutions, along with strategic consulting and organizational capability development into one company - and with one name—Amplity. Amplity is a new pure-play pharmaceutical commercialization partner that enjoys a 35-year track record. ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.amplity.com
  • 1000 Floral Vale Boulevard Suite 400
    Yardley, PA USA 19067
  • Phone: 215.525.9800

Executives

Name Title Contact Details
Pravin Wilfred
Chief Technology Officer Profile

Similar Companies

Envigo

Envigo provides essential products and research services for pharmaceutical, crop protection, and chemical companies as well as universities, governments, and other research organizations.

Myonexustx

Myonexus Therapeutics is a clinical stage, rare disease gene therapy company developing first-ever, corrective treatments for Limb-girdle muscular dystrophy.

SpaLab

SpaLab is a San Marcos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TransCode Therapeutics

TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company`s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.

Graybug Vision

Every day, Graybug Vision works relentlessly to make healthy vision more accessible and more manageable for patients with chronic vision-threatening eye diseases. We are a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of chronic diseases of the retina and optic nerve. Our novel technologies are designed to release drugs in ocular tissue at a controlled rate for up to 12 months in order to improve patient compliance, reduce healthcare burdens and, ultimately, deliver better clinical outcomes.